BioSpace News Archive

Business

With $50M, Vilya’s Peptides Aim to Transcend Cells’ Lipid Membrane

Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.

August 30, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Umoja’s Unified Approach to Exceeding the Limitations of Cell Therapy

Umoja CEO Andy Scharenberg spoke with BioSpace about the company’s unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.

August 30, 2022
·
9 min read
·
Heather McKenzie
Pfizer Invests $500K in Decentralized Collective Focused on Longevity R&D

Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment - in a decentralized drug development program driven by VitaDAO.

August 30, 2022
·
2 min read
·
Alex Keown
Drug Development

Jounce Falls on Missed Endpoint in Phase II NSCLC Study

Jounce Therapeutics announced that a Phase II trial assessing a combination treatment for non-small cell lung cancer failed to meet its primary endpoint.

August 30, 2022
·
2 min read
·
Alex Keown
Drug Development

Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates

Aria Pharmaceuticals secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs.

August 30, 2022
·
2 min read
·
Alex Keown
Policy

Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia

Moderna, Inc. announced that the Therapeutic Goods Administration in Australia has granted provisional approval for its Omicron-containing bivalent booster vaccine, mRNA-1273.214 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

August 30, 2022
·
5 min read
Policy

Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A

The U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for efanesoctocog alfa for the treatment of hemophilia A, a rare and life-threatening bleeding disorder.

August 30, 2022
·
9 min read
Drug Development

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans aQ4 2022 IND filingfor OK-101 to treat dry eye disease, with AmbioPharm playing a key role in peptide manufacturing and development.

August 30, 2022
·
5 min read
AlzeCure Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB announced that an abstract about the research platform NeuroRestore and its role in neuroprotection has been accepted for a presentation at ISMND 2022, which this year will be held in Athens, Greece, on October 10-12.

August 30, 2022
·
5 min read
Business

Promore Pharma Interim report January – June 2022

In August 2022, the company received a granted patent in the European Union for the use of the candidate drug ropocamptide (LL-37) for the treatment of chronic wounds.

August 30, 2022
·
5 min read